New leadership expands Huntington’s Disease Center of Excellence at UCI Health

• by

• July 10, 2026

FDA Clears Avulux Migraine Lenses

FDA De Novo authorization establishes a new device classification for lenses designed to reduce migraine-associated light sensitivity

• September 15, 2026

• 2 min

Correction: Microglial 5-LOX-activating protein antagonism alleviates leukotriene-driven neuroinflammation

• by Julia Konings, Fleur Mingneau, Serhii Chornyi, Cathrin E. Hansen, Rianne T. M. van der Burgt, Tessa G. van Elk, Laura Bolkaerts, Bo Batens, Gábor Tóth, Ingela Lanekoff, Frédéric M. Vaz, Alessio Cardilli, Marie Sels, Susanne M. A. van der Pol, Helga E. de Vries, Martin Giera, Oliver Werz, Sofie Kessels, Sanne G. S. Verberk, Jeroen F. J. Bogie, Merel Rijnsburger, Jerome J. A. Hendriks, Gijs Kooij

• September 4, 2026

Correction: From Metrics to Meaning in Neurological Rehabilitation: Clinicians’ Perspectives on Digital Metrics of Upper Limb Functioning—A Focus Group Study

• by Johannes Pohl, Laura Mayrhuber, Olivier Lambercy, Chris Easthope Awai

• September 11, 2026